Contineum Therapeutics (CTNM) is a pre-revenue clinical-stage biopharmaceutical company. Under a liquidation lens, recovery posture is positive at the balance-sheet level: total assets of $261.3M versus total liabilities of $11.3M yields reported book equity of $250.0M. The asset base is dominated by high-quality liquid instruments — cash and cash equivalents of $20.2M and current marketable securities of $226.2M, totaling $246.3M in cash, equivalents, and marketable securities per management disclosure. Under liquidation haircuts, cash recovers at 100% and the AFS debt securities portfolio (U.S. government agency, corporate debt, commercial paper, Yankee debt, ABS, CDs — all Level 1 or Level 2, all maturities under 3 years, de minimis unrealized losses of $363K on $165.7M in loss-position securities as of March 31, 2026) recovers very close to face. Intangibles are zero on balance sheet; PP&E net is $1.1M and is subject to a 50-70% haircut. Prepaid and other current assets of $6.6M are partially recoverable. The operating lease ROU asset of $7.0M gets zero recovery under liquidation while the corresponding $7.0M lease liability remains at face value — this is the primary structural offset to the otherwise clean balance sheet. No long-term debt. Accumulated deficit is $191.8M, consistent with cumulative cash consumption since inception. Quarterly cash burn from operations was $16.3M for Q1 2026 (slightly higher than Q1 2025's $14.4M). The company estimates current liquidity sufficient through at least 12 months. Compared to the December 31, 2025 10-K, total assets declined from approximately $277M to $261M, driven by deployment of cash into the marketable securities portfolio (investing outflows of $39.3M net) and operating burn. Accrued liabilities declined sharply from $6.4M to $2.9M primarily due to normal Q1 paydown of accrued compensation ($4.8M to $1.6M). The ATM facility was expanded in March 2026 to allow up to $100M in new sales, providing a capital access mechanism, but no shares were sold in Q1 2026 under the amended facility. The filing discusses approximately $1.0B in potential J&J milestone payments and tiered royalties in MD&A but these contingent assets are not separately tagged in XBRL and carry zero liquidation value as all variable consideration remains fully constrained. Unrecognized stock-based compensation of $40.9M is a future cash-equivalent obligation that does not appear on the liability side of the balance sheet but dilutes equity recovery.
▼ Community Notes